Shopping Cart

Your shopping cart is currently empty

AVE3085

Name: AVE3085
Brand: TargetMol
SKU: T14355
Price: 61 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T14355Cas No. 450348-85-3

Alias AVE-3085

AVE3085 is an endothelial nitric oxide synthase enhancer that restores endothelial function and reduces blood pressure in spontaneously hypertensive rats, used in cardiovascular disease research.

AVE3085

Copy Product Info

😃Good

Purity: 99.87%

Catalog No. T14355Alias AVE-3085Cas No. 450348-85-3

AVE3085 is an endothelial nitric oxide synthase enhancer that restores endothelial function and reduces blood pressure in spontaneously hypertensive rats, used in cardiovascular disease research.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$61	-	In Stock
5 mg	$147	-	In Stock
10 mg	$239	-	In Stock
25 mg	$455	-	In Stock
50 mg	$762	-	In Stock
100 mg	$1,190	-	In Stock
1 mL x 10 mM (in DMSO)	$98	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.87%

Appearance:Solid

Color:White

Resource Download

COA HPLC HNMR

Product Introduction

Bioactivity

Description	AVE3085 is an endothelial nitric oxide synthase enhancer that restores endothelial function and reduces blood pressure in spontaneously hypertensive rats, used in cardiovascular disease research.
In vitro	AVE3085 (10 μM) at 37°C for 60 min significantly increased the expression of eNOS and p-eNOS (Ser1177) in coronary endothelial cells. [3]
In vivo	Treatment of spontaneously hypertensive rats (SHR) with AVE3085 (10 mg/kg/day, oral) for 4 weeks greatly improved endothelum-dependent relaxation of the aorta in SHR and reduced blood pressure in SHR. [1] AVE3085 (10 mg/kg/day, taken orally) improves endothelial dysfunction in db/db mice, thereby reducing oxidative stress in blood vessel walls. [2]
Synonyms	AVE-3085

Chemical Properties

Molecular Weight	317.29
Formula	C₁₇H₁₃F₂NO₃
Cas No.	450348-85-3
Smiles	O=C(NC1CC=2C=CC=CC2C1)C3=CC=C4OC(F)(F)OC4=C3
Relative Density.	1.43 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 200 mg/mL (630.34 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Corn Oil: 3.3 mg/mL (10.4 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	3.1517 mL	15.7585 mL	31.5169 mL	157.5845 mL
5 mM	0.6303 mL	3.1517 mL	6.3034 mL	31.5169 mL
10 mM	0.3152 mL	1.5758 mL	3.1517 mL	15.7585 mL
20 mM	0.1576 mL	0.7879 mL	1.5758 mL	7.8792 mL
50 mM	0.0630 mL	0.3152 mL	0.6303 mL	3.1517 mL
100 mM	0.0315 mL	0.1576 mL	0.3152 mL	1.5758 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc